Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs.

MLA

Ornelas-Loredo, Aylin, et al. “Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs.” JAMA Cardiology, vol. 5, no. 1, Jan. 2020, pp. 57–64. EBSCOhost, https://doi.org/10.1001/jamacardio.2019.4513.

APA

Ornelas-Loredo, A., Kany, S., Abraham, V., Alzahrani, Z., Darbar, F. A., Sridhar, A., Ahmed, M., Alamar, I., Menon, A., Zhang, M., Chen, Y., Hong, L., Konda, S., & Darbar, D. (2020). Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs. JAMA Cardiology, 5(1), 57–64. https://doi.org/10.1001/jamacardio.2019.4513

Chicago

Ornelas-Loredo, Aylin, Shinwan Kany, Vihas Abraham, Zain Alzahrani, Faisal A Darbar, Arvind Sridhar, Maha Ahmed, et al. 2020. “Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs.” JAMA Cardiology 5 (1): 57–64. doi:10.1001/jamacardio.2019.4513.